Clinical and Survival Analysis of Primary Intestinal Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- VernacularTitle:原发性弥漫性大细胞性肠非霍奇金淋巴瘤的临床及生存分析
- Author:
Rong XIE
;
Xinlun HUANG
;
Xin DU
- Publication Type:Journal Article
- Keywords:
Intestinal,non-Hodgkin's lymphoma;
Primary
- From:
Journal of Chinese Physician
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical features, treatment and survival rate of primary intestinal diffuse large B-cell(DLCL) non-Hodgkin's lymphoma (NHL).Methods 28 cases of intestinal NHL having DLCL histology were retrospectively reviewed and analyzed. Results 79% patients were treated by surgery-chemotherapy.50% attained complete remission (CR),14% attained partial remission (PR), 36% were no response-progressive disease (NR-PD).Over a median followed-up for 62 months in all 28 patients, 7 (25%) were alive and disease free, 3 (11%) were alive with loading tomor, and the remaining 18 (64%) were dead.Conclusion This series clinical features, treatment and outcome of NHL patients with primary intestinal DLCL was reviewed. Surgery-chemotherapy is the common treatment, prospective randomized studies can ascertain the precise role of surgical resection in primary intestinal NHL.
